Education
About Us
Working with TipRanks
Follow Us
Aim Immunotech Inc. (AIM)
XASE:AIM
AIM Stock Chart & Stats
$1.35
>-$0.01(-4.03%)
At close: 4:00 PM EST
$1.35
>-$0.01(-4.03%)
Day’s Range― - ―
52-Week Range$1.07 - $36.27
Previous CloseN/A
Volume272.06K
Average Volume (3M)122.81K
Market Cap
$3.79M
Enterprise Value-$3.27K
Total Cash (Recent Filing)$2.41M
Total Debt (Recent Filing)$2.34M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Apr 07, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding2,941,620
10 Day Avg. Volume265,820
30 Day Avg. Volume122,805
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-8.47
Price to Sales (P/S)65.90
P/FCF Ratio-0.75
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-0.16
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.00Price Target Upside1529.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThirteen active clinical trials and positive Phase 2 Ampligen data create multiple potential clinical readouts that could materially improve investor confidence and valuation.
Financial RunwayRecent fundraising bolstered the balance sheet and provides cash into late-2026, supporting continued research and development without immediate capital strain.
Regulatory ProgressOngoing discussions with the FDA about pivotal study design for Ampligen suggest a clearer regulatory pathway that could enhance approval prospects if agreement is reached.
Bears Say
Listing And Governance HistoryA prior delisting from the NYSE American indicates past market or compliance instability that may continue to weigh on investor trust despite relisting.
Revenue GenerationMinimal revenue as an early-stage clinical company increases reliance on external financing and raises the risk of dilution or funding shortfalls.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $1.07 and its highest was $36.27 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $3.79M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Apr 07, 2026 which is in 87 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Aim Immunotech Inc. released its earnings results on Nov 18, 2025. The company reported -$1.57 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$0.595.
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate is -0.94.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 2,941,620 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Aim Immunotech Inc. reported an EPS of -$1.57 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went down -7.639%.
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
AIM Stock 12 Month Forecast
Average Price Target
$22.00
▲(1529.63% Upside)
Technical Analysis
Ownership Overview
61.15% Insiders
0.19% Mutual Funds
2.53% Other Institutional Investors
36.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---